273 related articles for article (PubMed ID: 26568279)
1. Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.
Ziemssen F; Sobolewska B; Deissler H; Deissler H
Expert Opin Drug Saf; 2016 Jan; 15(1):75-87. PubMed ID: 26568279
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
3. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
[TBL] [Abstract][Full Text] [Related]
5. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
Csaky K; Do DV
Am J Ophthalmol; 2009 Nov; 148(5):647-56. PubMed ID: 19712924
[TBL] [Abstract][Full Text] [Related]
6. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for neovascular ocular diseases.
Lynch SS; Cheng CM
Ann Pharmacother; 2007 Apr; 41(4):614-25. PubMed ID: 17355998
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
[TBL] [Abstract][Full Text] [Related]
10. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
[TBL] [Abstract][Full Text] [Related]
12. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
Wickremasinghe SS; Michalova K; Gilhotra J; Guymer RH; Harper CA; Wong TY; Qureshi S
Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
Chen CY; Wong TY; Heriot WJ
Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
16. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
17. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Hussain RM; Ciulla TA
Expert Opin Emerg Drugs; 2017 Sep; 22(3):235-246. PubMed ID: 28756707
[TBL] [Abstract][Full Text] [Related]
18. Preferred therapies for neovascular age-related macular degeneration.
Chiang A; Regillo CD
Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
20. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
Micieli JA; Santiago P; Brent MH
Acta Ophthalmol; 2011 Feb; 89(1):e99-100. PubMed ID: 19925526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
